[1] |
Quillin SJ, Seifert HS. Neisseria gonorrhoeae host adaptation and pathogenesis[J]. Nat Rev Microbiol, 2018,16(4):226⁃240. doi: 10.1038/nrmicro.2017.169.
|
[2] |
Workowski KA, Bachmann LH, Chan PA, et al. Sexually transmitted infections treatment guidelines, 2021[J]. MMWR Recomm Rep, 2021,70(4):1⁃187. doi: 10.15585/mmwr.rr7004a1.
|
[3] |
Fifer H, Saunders J, Soni S, et al. 2018 UK national guideline for the management of infection with Neisseria gonorrhoeae[J]. Int J STD AIDS, 2020,31(1):4⁃15. doi: 10.1177/09564624198 86775.
|
[4] |
Chen SC, Han Y, Yuan LF, et al. Identification of internationally disseminated ceftriaxone⁃resistant Neisseria gonorrhoeae strain FC428, China[J]. Emerg Infect Dis, 2019,25(7):1427⁃1429. doi: 10.3201/eid2507.190172.
|
[5] |
Williamson DA, Fairley CK, Howden BP, et al. Trends and risk factors for antimicrobial⁃resistant Neisseria gonorrhoeae, Melbourne, Australia, 2007 to 2018[J]. Antimicrob Agents Chemother, 2019,63(10): e01221⁃19. doi: 10.1128/AAC.01221⁃19.
|
[6] |
陈绍椿, 刘经纬, 周可, 等. 头孢曲松耐药淋病奈瑟菌株FC428的流行、耐药机制及应对策略[J]. 中华皮肤科杂志, 2022,55(12):1122⁃1126. doi: 10.35541/cjd.20200528.
|
[7] |
Seña AC, Bachmann L, Johnston C, et al. Optimising treatments for sexually transmitted infections: surveillance, pharmacokinetics and pharmacodynamics, therapeutic strategies, and molecular resistance prediction[J]. Lancet Infect Dis, 2020,20(8):e181⁃e191. doi: 10.1016/S1473⁃3099(20)30171⁃7.
|
[8] |
Campoccia D, Montanaro L, Arciola CR. A review of the biomaterials technologies for infection⁃resistant surfaces[J]. Biomaterials, 2013,34(34):8533⁃8554. doi: 10.1016/j.biomaterials.2013.07.089.
|
[9] |
Kirkcaldy RD, Weinstock HS, Moore PC, et al. The efficacy and safety of gentamicin plus azithromycin and gemifloxacin plus azithromycin as treatment of uncomplicated gonorrhea[J]. Clin Infect Dis, 2014,59(8):1083⁃1091. doi: 10.1093/cid/ciu521.
|
[10] |
刘经纬, 徐文绮, 朱小宇, 等. 大连地区淋球菌分离株对庆大霉素的敏感性[J]. 国际流行病学传染病学杂志, 2019,46(4):310⁃312. doi: 10.3760/cma.j.issn.1673⁃4149.2019.04.013.
|
[11] |
Matoga M, Chen JS, Krysiak R, et al. Gentamicin susceptibility in Neisseria gonorrhoeae and treatment outcomes for urogenital gonorrhea after 25 years of sustained gentamicin use in Malawi[J]. Sex Transm Dis, 2022,49(4):251⁃256. doi: 10.1097/OLQ. 0000000000001580.
|
[12] |
Unemo M, Ballard R, Ison C, et al. Laboratory diagnosis of sexually transmitted infections, including human immunodeficiency virus[M]. Geneva: World Health Organization,2013. https://www.who.int/publications/i/item/9789241505840.
|
[13] |
CLSI. Performance standards for antimicrobial susceptibility testing [M]. 31st ed. Wayne, PA: Clinical and Laboratory Standards Institute, 2021. https://clsi.org/media/tc4b1paf/m10033_samplepages⁃ 1.pdf.
|
[14] |
Yang F, Yan J, Zhang J, et al. Evaluation of alternative antibiotics for susceptibility of gonococcal isolates from China[J]. Int J Antimicrob Agents, 2020,55(2):105846. doi: 10.1016/j.ijantimicag.2019.11.003.
|
[15] |
Li X, Le W, Lou X, et al. In vitro efficacy of gentamicin alone and in combination with ceftriaxone, ertapenem, and azithromycin against multidrug⁃resistant Neisseria gonorrhoeae[J]. Microbiol Spectr, 2021,9(2):e0018121. doi: 10.1128/Spectrum.00181⁃21.
|
[16] |
Liu JW, Xu WQ, Zhu XY, et al. Gentamicin susceptibility of Neisseria gonorrhoeae isolates from 7 provinces in China[J]. Infect Drug Resist, 2019,12:2471⁃2476. doi: 10.2147/IDR.S214059.
|
[17] |
Xu W, Zhou Q, Liu J, et al. In vitro study of the interaction of gentamicin with ceftriaxone and azithromycin against Neisseria gonorrhoeae using agar dilution method[J]. Antibiotics (Basel), 2022,11(8):1083. doi: 10.3390/antibiotics11081083.
|
[18] |
Dowell D, Kirkcaldy RD. Effectiveness of gentamicin for gonorrhoea treatment: systematic review and meta⁃analysis[J]. Sex Transm Infect, 2012,88(8):589⁃594. doi: 10.1136/sextrans⁃2012⁃050604.
|